Back to Search
Start Over
Phosphodiesterase 5 inhibitors: current status and potential applications
- Source :
- Nature Reviews Drug Discovery. 1:674-682
- Publication Year :
- 2002
- Publisher :
- Springer Science and Business Media LLC, 2002.
-
Abstract
- Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clinical experience with sildenafil and other new PDE5 inhibitors. Research in the field continues at a substantial level to identify new, selective PDE5 inhibitors and to investigate their usefulness and activity in other areas. This review summarizes recent clinical trials with PDE5 inhibitors, advances in medicinal chemistry, and other activities and potential applications of this class of compounds.
- Subjects :
- Male
Phosphodiesterase Inhibitors
Sildenafil
Chemistry, Pharmaceutical
Pharmacology
Biology
Piperazines
Sildenafil Citrate
Tadalafil
Structure-Activity Relationship
chemistry.chemical_compound
Cyclic gmp
Erectile Dysfunction
Vardenafil Dihydrochloride
Drug Discovery
medicine
Humans
Sulfones
Clinical Trials as Topic
Phosphoric Diester Hydrolases
Triazines
Imidazoles
Phosphodiesterase
VARDENAFIL DIHYDROCHLORIDE
General Medicine
medicine.disease
Clinical trial
Erectile dysfunction
chemistry
Purines
cGMP-specific phosphodiesterase type 5
Carbolines
medicine.drug
Subjects
Details
- ISSN :
- 14741784 and 14741776
- Volume :
- 1
- Database :
- OpenAIRE
- Journal :
- Nature Reviews Drug Discovery
- Accession number :
- edsair.doi.dedup.....e40a11191e91f0c7ab709a75896187e2